10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Sylvain Chantepie, Walter J. F. M. van der Velden et al.|The Lancet Haematology|2023Cited by 39
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study groupMichael Lübbert, Gerwin Huls, Pierre W. Wijermans et al.|Blood|2025Cited by 1